Request Trial
shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026   The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.
Pharma
Mylan throws down new gauntlet in Novo Wegovy patent fight
25 September 2026   Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Fish & Richardson nets patent litigator to grow European practice
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Takeda sees off UK challenge to Elvanse SPC
Conley Rose welcomes back former employee with legal and business nous
Mylan throws down new gauntlet in Novo Wegovy patent fight
Novartis defeats Orange Book challenge but suffers EU setback
Behind the case: How Novartis defended its blockbuster Entresto in the UK
Leading European patent litigator to join Carpmaels & Ransford